WALTHAM, Mass. and BOULDER, Colo. - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology firm engaged in creating precision therapies for genetic diseases, has introduced a new KRAS inhibitor to its developmental pipeline, as per a recent announcement. The company presented preclinical data on the KRAS inhibitor and an H1047R mutant-selective PI3Kα inhibitor at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, on Wednesday.
Cogent's KRAS inhibitor, currently in the discovery stage, has shown selectivity over HRAS and NRAS, with activity across prevalent KRAS mutations. The KRAS gene is often mutated in cancers like colorectal, non-small cell lung, and pancreatic cancer. The company's internal studies suggest their KRAS inhibitor, CGT6737, may provide significant tumor growth inhibition in preclinical models.
In parallel, Cogent is advancing CGT6297, a PI3Kα inhibitor selective for the H1047R mutation, found in over 55,000 cancer patients annually. The inhibitor is designed to spare the wild-type PI3Kα, potentially offering a better safety profile than existing treatments. CGT6297 has demonstrated potent inhibition of tumor growth in animal models without increasing insulin levels, a common issue with current therapies. The company plans to begin IND-enabling studies for CGT6297 in 2025.
Andrew Robbins, President and CEO of Cogent, expressed confidence in the potential of these new molecules to become best-in-class therapies for patients with genetically defined diseases. He emphasized that these developments align with the company's strategy to create impactful treatments.
Cogent Biosciences will also participate in the Guggenheim Healthcare Innovation Conference on November 12, 2024, with a live webcast available on their website.
While Cogent's press release contains forward-looking statements, these are based on current expectations and are subject to risks and uncertainties that could affect the actual outcomes. The company's most recent SEC filings detail these risks under "Risk Factors."
This news article is based on a press release statement from Cogent Biosciences, Inc.
In other recent news, Cogent Biosciences has seen a variety of adjustments to their stock price targets and ratings from various financial firms, following recent developments in their clinical trials. Citi raised its price target for Cogent from $13.00 to $15.00, maintaining a Buy rating due to the potential of Cogent's KIT inhibitor drug, bezuclastinib. The company's pivotal trials for this drug are expected to yield results for advanced systemic mastocytosis in mid-2025, and for non-advanced systemic mastocytosis and gastrointestinal stromal tumors in the latter half of 2025.
Additionally, Baird increased its price target on Cogent shares to $10.00, while keeping a Neutral rating, following the completion of patient enrollment for its PEAK study in GIST. H.C. Wainwright reduced its 12-month price target for Cogent to $17, but reaffirmed a Buy rating. Piper Sandler reaffirmed its Overweight rating with a $22.00 price target.
These adjustments come in light of recent progress in Cogent's clinical trials. The company announced the successful completion of enrollment for its Phase 3 PEAK trial, which is evaluating bezuclastinib for the treatment of gastrointestinal stromal tumors. Top-line results from this trial are expected by the end of 2025. Additionally, Cogent's SUMMIT trial, aimed at treating nonadvanced systemic mastocytosis, is on track to complete enrollment in the first quarter of 2025, with results expected in the second half of the same year.
InvestingPro Insights
Cogent Biosciences' recent announcement of a new KRAS inhibitor and promising preclinical data aligns with the company's strong market performance. According to InvestingPro data, Cogent has seen impressive price returns, with a 75.86% increase over the past six months and a substantial 108.16% year-to-date return. This upward trajectory has brought the stock to trade near its 52-week high, with the current price at 99.19% of that peak.
Despite these positive market indicators, InvestingPro Tips reveal that Cogent is not currently profitable, with analysts not anticipating profitability this year. This is reflected in the company's adjusted operating income of -$244.6 million for the last twelve months as of Q2 2023. However, the company's financial health shows some strength, as it holds more cash than debt on its balance sheet and its liquid assets exceed short-term obligations.
The biotechnology sector often sees companies operating at a loss while developing potentially groundbreaking therapies. Cogent's focus on precision therapies for genetic diseases, including the newly announced KRAS inhibitor and PI3Kα inhibitor, could explain the market's optimistic outlook despite current financial losses.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Cogent Biosciences, providing a deeper understanding of the company's financial position and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.